SI2510947T1 - Sestavki za imunizacijo proti Staphylococcus aureus - Google Patents

Sestavki za imunizacijo proti Staphylococcus aureus

Info

Publication number
SI2510947T1
SI2510947T1 SI201031163A SI201031163A SI2510947T1 SI 2510947 T1 SI2510947 T1 SI 2510947T1 SI 201031163 A SI201031163 A SI 201031163A SI 201031163 A SI201031163 A SI 201031163A SI 2510947 T1 SI2510947 T1 SI 2510947T1
Authority
SI
Slovenia
Prior art keywords
compositions
staphylococcus aureus
against staphylococcus
immunising against
immunising
Prior art date
Application number
SI201031163A
Other languages
English (en)
Slovenian (sl)
Inventor
Fabio Bagnoli
Massimiliano Biagini
Luigi Fiaschi
Guido Grandi
Ravi Mishra
Nathalie Norais
Maria Scarselli
Original Assignee
Glaxosmithkline Biologicals S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42734088&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI2510947(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Biologicals S.A. filed Critical Glaxosmithkline Biologicals S.A.
Publication of SI2510947T1 publication Critical patent/SI2510947T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SI201031163A 2009-04-14 2010-04-14 Sestavki za imunizacijo proti Staphylococcus aureus SI2510947T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21270509P 2009-04-14 2009-04-14
US23407909P 2009-08-14 2009-08-14
EP12175868.4A EP2510947B1 (en) 2009-04-14 2010-04-14 Compositions for immunising against Staphylococcus aureus

Publications (1)

Publication Number Publication Date
SI2510947T1 true SI2510947T1 (sl) 2016-05-31

Family

ID=42734088

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201031163A SI2510947T1 (sl) 2009-04-14 2010-04-14 Sestavki za imunizacijo proti Staphylococcus aureus

Country Status (24)

Country Link
US (5) US8679505B2 (enExample)
EP (3) EP2419129A2 (enExample)
JP (5) JP5830009B2 (enExample)
KR (1) KR20120034612A (enExample)
CN (2) CN109248313B (enExample)
AU (1) AU2010238255B2 (enExample)
BR (1) BRPI1013780B8 (enExample)
CA (2) CA3154626A1 (enExample)
CO (1) CO6440592A2 (enExample)
DK (1) DK2510947T3 (enExample)
ES (1) ES2565377T3 (enExample)
HR (1) HRP20160276T1 (enExample)
HU (1) HUE028803T2 (enExample)
IL (1) IL215593A0 (enExample)
MX (3) MX363222B (enExample)
NZ (2) NZ612315A (enExample)
PH (1) PH12015500092A1 (enExample)
PL (1) PL2510947T3 (enExample)
RU (2) RU2508126C2 (enExample)
SG (2) SG175092A1 (enExample)
SI (1) SI2510947T1 (enExample)
SM (1) SMT201600117B (enExample)
WO (1) WO2010119343A2 (enExample)
ZA (1) ZA201302878B (enExample)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007536644A (ja) * 2004-05-06 2007-12-13 ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア 画像を整列させ分類するための方法およびシステム
EP2368570A3 (en) * 2006-01-18 2012-05-02 University Of Chicago Compositions and methods related to staphylococcal bacterium proteins
US9181329B2 (en) 2007-08-31 2015-11-10 The University Of Chicago Methods and compositions related to immunizing against Staphylococcal lung diseases and conditions
ES2565377T3 (es) * 2009-04-14 2016-04-04 Glaxosmithkline Biologicals Sa Composiciones para inmunización contra Staphylococcus aureus
EA026401B1 (ru) 2009-09-02 2017-04-28 Новартис Аг Иммуногенные композиции, содержащие модуляторы активности tlr
US8808699B2 (en) 2010-04-05 2014-08-19 The University Of Chicago Compositions and methods related to protein A (SpA) antibodies as an enhancer of immune response
KR20190133290A (ko) 2010-05-05 2019-12-02 뉴욕 유니버시티 스타필로코커스 아우레우스 류코시딘, 치료 조성물 및 그것의 용도
SI2590676T1 (sl) 2010-07-06 2016-11-30 Glaxosmithkline Biologicals, S.A. Virionu podobni delci za dajanje za samorepliciranje RNA molekul
US9770463B2 (en) 2010-07-06 2017-09-26 Glaxosmithkline Biologicals Sa Delivery of RNA to different cell types
PL2590626T3 (pl) 2010-07-06 2016-04-29 Glaxosmithkline Biologicals Sa Liposomy z lipidami o korzystnej wartości pka do dostarczania rna
ES2586580T3 (es) 2010-07-06 2016-10-17 Glaxosmithkline Biologicals Sa Inmunización de mamíferos grandes con dosis bajas de ARN
SI3243526T1 (sl) 2010-07-06 2020-02-28 Glaxosmithkline Biologicals S.A. Dostava RNA za sprožitev večih imunskih poti
CN103384515B (zh) 2010-08-31 2017-02-15 诺华有限公司 适用于脂质体递送编码蛋白质的rna的脂质
SI3970742T1 (sl) 2010-08-31 2022-08-31 Glaxosmithkline Biologicals S.A. Pegilirani liposomi za dostavo RNA, ki kodira imunogen
ES2458355T3 (es) 2010-09-01 2014-05-05 Novartis Ag Adsorción de inmunopotenciadores sobre sales metálicas insolubles
WO2012034067A1 (en) 2010-09-09 2012-03-15 The University Of Chicago Methods and compositions involving protective staphylococcal antigens
BR112013008700B8 (pt) 2010-10-11 2022-10-04 Novartis Ag Molécula de rna auto-replicante, partícula de replicon de alfavírus, composição, molécula de dna recombinante, uso da molécula de rna auto-replicante
US9618508B2 (en) 2010-12-14 2017-04-11 Glaxosmithkline Biologicals Sa Flow cytometry analysis of materials adsorbed to metal salts
AU2012214677B2 (en) * 2011-02-08 2016-11-10 Abvacc, Inc. Immunogenic composition comprising alpha-hemolysin oligopeptides
BR112013022397A2 (pt) 2011-03-02 2017-09-26 Derek O’Hagan vacinas combinadas com doses menores de antígeno e/ou adjuvante
WO2012136653A1 (en) 2011-04-08 2012-10-11 Novvac Aps Proteins and nucleic acids useful in vaccines targeting staphylococcus aureus
US8945588B2 (en) 2011-05-06 2015-02-03 The University Of Chicago Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides
CA2835628C (en) 2011-05-11 2023-01-03 Children's Medical Center Corporation Multiple antigen presenting immunogenic composition, and methods and uses thereof
BR112013032911A2 (pt) 2011-06-19 2017-01-24 Univ New York leucotoxina e/d como um novo agente anti-inflamatório e microbicida
CN103717234A (zh) 2011-06-19 2014-04-09 纽约大学 治疗和预防金黄色葡萄球菌感染及相关病状的方法
SG10201605537XA (en) 2011-07-06 2016-09-29 Novartis Ag Liposomes having useful n:p ratio for delivery of rna molecules
US11896636B2 (en) 2011-07-06 2024-02-13 Glaxosmithkline Biologicals Sa Immunogenic combination compositions and uses thereof
FR2977800B1 (fr) 2011-07-13 2014-03-14 Sanofi Pasteur Composition vaccinale avec des nanoparticules d'hydroxyde d'aluminium
PT2750707T (pt) 2011-08-31 2019-01-23 Glaxosmithkline Biologicals Sa Lipossomas peguilados para distribuição de arn que codifica imunogénio
WO2013030378A1 (en) * 2011-09-01 2013-03-07 Novartis Ag Adjuvanted formulations of staphylococcus aureus antigens
CN104023744A (zh) * 2011-12-23 2014-09-03 诺华股份有限公司 用于针对金黄色葡萄球菌免疫的稳定组合物
JP2015510872A (ja) 2012-03-07 2015-04-13 ノバルティス アーゲー Ｓｔｒｅｐｔｏｃｏｃｃｕｓｐｎｅｕｍｏｎｉａｅ抗原の増強された製剤
RU2014140336A (ru) 2012-03-07 2016-04-27 Новартис Аг Иммунологически полезные соли аргинина
RU2014140521A (ru) 2012-03-08 2016-04-27 Новартис Аг Адъювантные составы бустерных вакцин
NZ702285A (en) * 2012-04-26 2016-07-29 Univ Chicago Staphylococcal coagulase antigens and methods of their use
WO2014011645A1 (en) * 2012-07-10 2014-01-16 Merck Sharp & Dohme Corp. Protective vaccine based on staphylococcus aureus sa2493 protein
WO2014033191A1 (en) 2012-08-31 2014-03-06 Novartis Ag Stabilised proteins for immunising against staphylococcus aureus
ES2737024T3 (es) * 2012-08-31 2020-01-09 Glaxosmithkline Biologicals Sa Proteínas estabilizadas para inmunización contra Staphylococcus aureus
EP2890387A1 (en) * 2012-08-31 2015-07-08 Novartis AG Stabilised proteins for immunising against staphylococcus aureus
WO2014033193A1 (en) * 2012-08-31 2014-03-06 Novartis Ag Stabilised proteins for immunising against staphylococcus aureus
US9764027B2 (en) 2012-09-18 2017-09-19 Glaxosmithkline Biologicals Sa Outer membrane vesicles
CN102993308B (zh) * 2012-09-29 2014-11-05 重庆原伦生物科技有限公司 耐甲氧西林金黄色葡萄球菌（mrsa）疫苗重组蛋白抗原hi2及制备方法和应用
GB201217868D0 (en) * 2012-10-05 2012-11-21 Isis Innovation Staphyolococcus aureus antigens
JP6352950B2 (ja) 2013-03-08 2018-07-04 ノバルティス アーゲー 活性薬物の送達のための脂質と脂質組成物
EP3441474B1 (en) * 2013-06-18 2020-07-22 New York University Pharmaceutical compositions containing a mutated leukocidin e
ES3012932T3 (en) * 2013-12-03 2025-04-10 Evaxion Biotech As Proteins and nucleic acids useful in vaccines targeting staphylococcus aureus
BR112016013514B1 (pt) 2013-12-13 2022-04-19 Stora Enso Oyj (Fi) Papelão de múltiplas camadas
EP4019506A1 (en) 2013-12-19 2022-06-29 Novartis AG Lipids and lipid compositions for the delivery of active agents
US10059655B2 (en) 2013-12-19 2018-08-28 Novartis Ag Lipids and lipid compositions for the delivery of active agents
BE1022359B1 (fr) * 2014-03-17 2016-03-25 Glaxosmithkline Biologicals Sa Immunisation contre des infections staphylococciques des os et des articulations
BE1022875B1 (fr) * 2014-03-26 2016-09-30 Glaxosmithkline Biologicals S.A. Compositions pour une immunisation contre staphylococcus aureus
JP6894237B2 (ja) * 2014-03-26 2021-06-30 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 変異体ブドウ球菌抗原
WO2015162100A1 (en) * 2014-04-21 2015-10-29 Novartis Ag Vaccine adjuvants
EP4223285A3 (en) 2014-07-16 2023-11-22 Novartis AG Method of encapsulating a nucleic acid in a lipid nanoparticle host
ES2969956T3 (es) 2014-09-05 2024-05-23 Novartis Ag Lípidos y composiciones lipídicas para el suministro de agentes activos
WO2016095832A1 (en) * 2014-12-18 2016-06-23 The University Of Hong Kong Immunotherapeutic targets against staphylococcus aureus
EP3061826A1 (en) 2015-02-27 2016-08-31 Novartis AG Flavivirus replicons
EP3302532A4 (en) 2015-06-05 2019-01-09 New York University COMPOSITIONS AND METHODS FOR BIOLOGICAL ACTIVE AGGREGATES AGAINST STAPHYLOKOKEN
CN108137656A (zh) * 2015-09-24 2018-06-08 豪夫迈·罗氏有限公司 α-溶血素变体
CN108367062B (zh) 2015-10-13 2022-05-06 赛诺菲巴斯德有限公司 抗金黄色葡萄球菌的免疫原性组合物
WO2017137954A2 (en) * 2016-02-12 2017-08-17 The University Of Chicago Compositions and methods related to antibodies that neutralize coagulase activity during staphylococcus aureus disease
US10738338B2 (en) 2016-10-18 2020-08-11 The Research Foundation for the State University Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate
US11324815B2 (en) * 2016-10-21 2022-05-10 Socpra—Sciences et Genie, S.E.C. Vaccine constructs and uses thereof against Staphylococcus infections
CN107224576A (zh) * 2017-03-06 2017-10-03 浙江海隆生物科技有限公司 奶牛金黄色葡萄球菌乳房炎亚单位的疫苗及其制备方法和应用
CN110730670A (zh) * 2017-03-28 2020-01-24 儿童医疗中心有限公司 基于多抗原提呈系统(maps)的金黄色葡萄球菌疫苗、免疫原性组合物以及它们的用途
CN107827961B (zh) * 2017-10-11 2020-05-26 深圳市南山区人民医院 用于金黄色葡萄球菌Staphopain B蛋白检测的B细胞抗原表位肽及其试剂盒
GB201721576D0 (en) * 2017-12-21 2018-02-07 Glaxosmithkline Biologicals Sa Hla antigens and glycoconjugates thereof
US20210214421A1 (en) * 2018-03-21 2021-07-15 Doderm Gmbh Treatment of staphylococcus related diseases
US20200087361A1 (en) 2018-09-12 2020-03-19 The Children's Medical Center Corporation Pneumococcal fusion protein vaccines
KR102205620B1 (ko) 2019-05-16 2021-01-21 한국과학기술연구원 혈중 내 극소량 존재하는 miRNA의 검출 효율의 증가 방법
CN110256556A (zh) * 2019-06-28 2019-09-20 成都欧林生物科技股份有限公司 一种耐甲氧西林金黄色葡萄球菌人免疫球蛋白及制备方法
EP4077356A1 (en) * 2019-12-19 2022-10-26 GlaxoSmithKline Biologicals SA S. aureus antigens and compositions thereof
CA3166364A1 (en) * 2019-12-31 2021-07-08 Antagonis Compositions and methods for the prevention of s. aureus infection
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
MX2023004371A (es) 2020-10-14 2023-07-26 George Mason Res Foundation Inc Lípidos ionizables, y métodos de fabricación y uso de los mismos.
CN112851770B (zh) * 2021-02-05 2022-10-04 中国人民解放军陆军军医大学 一种用于诊断或防治金黄色葡萄球菌感染的α溶血素抗原表位肽及其应用
EP4387597A1 (en) 2021-08-16 2024-06-26 GlaxoSmithKline Biologicals SA Freeze-drying of lipid nanoparticles (lnps) encapsulating rna and formulations thereof
US20250134824A1 (en) 2021-08-16 2025-05-01 Glaxosmithkline Biologicals Sa Low-dose lyophilized rna vaccines and methods for preparing and using the same
CN116179663B (zh) * 2023-01-30 2023-12-22 天津大学 一种基于γ-溶血素纳米孔道收缩区实现核酸单分子片段式测序的方法
GB202303019D0 (en) 2023-03-01 2023-04-12 Glaxosmithkline Biologicals Sa Method of lyophilisation
AU2024234022A1 (en) * 2023-03-09 2025-08-28 BioNTech SE Peptidoglycan hydrolases with bactericidal activity
GB202311382D0 (en) 2023-07-25 2023-09-06 Glaxosmithkline Biologicals Sa Lyophilised compostion
CN118480136B (zh) * 2024-06-19 2025-01-14 南京澄实生物医药科技有限公司 一种预防和治疗金黄色葡萄球菌感染的免疫原性组合物
CN118858626B (zh) * 2024-09-20 2025-01-03 吉林大学 一种用于检测血浆金黄色葡萄球菌抗体的检测试剂、试剂盒及方法

Family Cites Families (182)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4057685A (en) 1972-02-02 1977-11-08 Abbott Laboratories Chemically modified endotoxin immunizing agent
US4356170A (en) 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
US4673574A (en) 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
US4459286A (en) 1983-01-31 1984-07-10 Merck & Co., Inc. Coupled H. influenzae type B vaccine
US4663160A (en) 1983-03-14 1987-05-05 Miles Laboratories, Inc. Vaccines for gram-negative bacteria
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4761283A (en) 1983-07-05 1988-08-02 The University Of Rochester Immunogenic conjugates
IL73534A (en) 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
US6090406A (en) 1984-04-12 2000-07-18 The Liposome Company, Inc. Potentiation of immune responses with liposomal adjuvants
US5916588A (en) 1984-04-12 1999-06-29 The Liposome Company, Inc. Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use
US4695624A (en) 1984-05-10 1987-09-22 Merck & Co., Inc. Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
US4882317A (en) 1984-05-10 1989-11-21 Merck & Co., Inc. Covalently-modified bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers and methods of preparing such polysaccharides and conjugataes and of confirming covalency
US4808700A (en) 1984-07-09 1989-02-28 Praxis Biologics, Inc. Immunogenic conjugates of non-toxic E. coli LT-B enterotoxin subunit and capsular polymers
IT1187753B (it) 1985-07-05 1987-12-23 Sclavo Spa Coniugati glicoproteici ad attivita' immunogenica trivalente
US4777127A (en) 1985-09-30 1988-10-11 Labsystems Oy Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
US4680338A (en) 1985-10-17 1987-07-14 Immunomedics, Inc. Bifunctional linker
US5011828A (en) 1985-11-15 1991-04-30 Michael Goodman Immunostimulating guanine derivatives, compositions and methods
GB8702816D0 (en) 1987-02-07 1987-03-11 Al Sumidaie A M K Obtaining retrovirus-containing fraction
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US5206152A (en) 1988-04-08 1993-04-27 Arch Development Corporation Cloning and expression of early growth regulatory protein genes
US5422120A (en) 1988-05-30 1995-06-06 Depotech Corporation Heterovesicular liposomes
AP129A (en) 1988-06-03 1991-04-17 Smithkline Biologicals S A Expression of retrovirus gag protein eukaryotic cells
NL8802046A (nl) 1988-08-18 1990-03-16 Gen Electric Polymeermengsel met polyester en alkaansulfonaat, daaruit gevormde voorwerpen.
AU627226B2 (en) 1988-08-25 1992-08-20 Liposome Company, Inc., The Influenza vaccine and novel adjuvants
DE3841091A1 (de) 1988-12-07 1990-06-13 Behringwerke Ag Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung
US5238944A (en) 1988-12-15 1993-08-24 Riker Laboratories, Inc. Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
CA2006700A1 (en) 1989-01-17 1990-07-17 Antonello Pessi Synthetic peptides and their use as universal carriers for the preparation of immunogenic conjugates suitable for the development of synthetic vaccines
JP2752788B2 (ja) 1989-01-23 1998-05-18 カイロン コーポレイション 感染および過剰増殖障害の為の組換え療法
DK0737750T3 (da) 1989-03-21 2003-09-01 Vical Inc Ekspression af exogene polynucleotidsekvenser i vertebrater
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US4929624A (en) 1989-03-23 1990-05-29 Minnesota Mining And Manufacturing Company Olefinic 1H-imidazo(4,5-c)quinolin-4-amines
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
EP0482068A1 (en) 1989-07-14 1992-04-29 American Cyanamid Company Cytokine and hormone carriers for conjugate vaccines
AU648261B2 (en) 1989-08-18 1994-04-21 Novartis Vaccines And Diagnostics, Inc. Recombinant retroviruses delivering vector constructs to target cells
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US4988815A (en) 1989-10-26 1991-01-29 Riker Laboratories, Inc. 3-Amino or 3-nitro quinoline compounds which are intermediates in preparing 1H-imidazo[4,5-c]quinolines
IT1237764B (it) 1989-11-10 1993-06-17 Eniricerche Spa Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
ZA911974B (en) 1990-03-21 1994-08-22 Res Dev Foundation Heterovesicular liposomes
US5658731A (en) 1990-04-09 1997-08-19 Europaisches Laboratorium Fur Molekularbiologie 2'-O-alkylnucleotides as well as polymers which contain such nucleotides
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
US5149655A (en) 1990-06-21 1992-09-22 Agracetus, Inc. Apparatus for genetic transformation
GB2276169A (en) 1990-07-05 1994-09-21 Celltech Ltd Antibodies specific for carcinoembryonic antigen
DE69113564T2 (de) 1990-08-13 1996-05-30 American Cyanamid Co Faser-Hemagglutinin von Bordetella pertussis als Träger für konjugierten Impfstoff.
NZ239643A (en) * 1990-09-17 1996-05-28 North American Vaccine Inc Vaccine containing bacterial polysaccharide protein conjugate and adjuvant (c-nd-che-a-co-b-r) with a long chain alkyl group.
CA2098849C (en) 1990-12-20 2007-07-10 Ralph R. Weichselbaum Control of gene expression by ionizing radiation
US5389640A (en) 1991-03-01 1995-02-14 Minnesota Mining And Manufacturing Company 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
SG46492A1 (en) 1991-03-01 1998-02-20 Minnesota Mining & Mfg 1-Substituted 2-substituted 1H-imidazo [4,5-c] quinolin-4-amines
ATE237694T1 (de) 1991-08-20 2003-05-15 Us Gov Health & Human Serv Adenovirus vermittelter gentransfer in den gastrointestinaltrakt
US5936076A (en) 1991-08-29 1999-08-10 Kirin Beer Kabushiki Kaisha αgalactosylceramide derivatives
US5268376A (en) 1991-09-04 1993-12-07 Minnesota Mining And Manufacturing Company 1-substituted 1H-imidazo[4,5-c]quinolin-4-amines
US5266575A (en) 1991-11-06 1993-11-30 Minnesota Mining And Manufacturing Company 2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines
WO1993010218A1 (en) 1991-11-14 1993-05-27 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Vectors including foreign genes and negative selective markers
GB9125623D0 (en) 1991-12-02 1992-01-29 Dynal As Cell modification
IT1262896B (it) 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
FR2688514A1 (fr) 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
IL105325A (en) 1992-04-16 1996-11-14 Minnesota Mining & Mfg Immunogen/vaccine adjuvant composition
JPH07507689A (ja) 1992-06-08 1995-08-31 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 特定組織のターゲティング方法及び組成物
JPH09507741A (ja) 1992-06-10 1997-08-12 アメリカ合衆国 ヒト血清による不活性化に耐性のあるベクター粒子
SK279188B6 (sk) 1992-06-25 1998-07-08 Smithkline Beecham Biologicals S.A. Vakcínová kompozícia spôsob jej prípravy a použiti
IL102687A (en) 1992-07-30 1997-06-10 Yeda Res & Dev Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
GB2269175A (en) 1992-07-31 1994-02-02 Imperial College Retroviral vectors
AU680459B2 (en) 1992-12-03 1997-07-31 Genzyme Corporation Gene therapy for cystic fibrosis
US5395937A (en) 1993-01-29 1995-03-07 Minnesota Mining And Manufacturing Company Process for preparing quinoline amines
ES2162139T5 (es) 1993-03-23 2008-05-16 Smithkline Beecham Biologicals S.A. Composiciones de vacuna que contienen monofosforil-lipido a 3-o-desacilado.
US5759573A (en) 1993-04-22 1998-06-02 Depotech Corporation Cyclodextrin liposomes encapsulating pharmacologic compounds and methods for their use
DE69434486T2 (de) 1993-06-24 2006-07-06 Advec Inc. Adenovirus vektoren für gentherapie
WO1995002597A1 (en) 1993-07-15 1995-01-26 Minnesota Mining And Manufacturing Company IMIDAZO[4,5-c]PYRIDIN-4-AMINES
US5352784A (en) 1993-07-15 1994-10-04 Minnesota Mining And Manufacturing Company Fused cycloalkylimidazopyridines
ATE440957T1 (de) 1993-09-15 2009-09-15 Novartis Vaccines & Diagnostic Rekombinante alphavirus vektoren
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
BR9407956A (pt) 1993-10-25 1996-11-26 Canji Inc Composiçao farmacêutica vetor de express o de adenovirus recombinante e kit par reduzir a proliferaçao de células tumorais
WO1995011700A1 (en) 1993-10-29 1995-05-04 Pharmos Corp. Submicron emulsions as vaccine adjuvants
CN1099868C (zh) 1993-11-16 2003-01-29 斯卡法玛公司 具有控制释放活性成分作用的囊
GB9326174D0 (en) 1993-12-22 1994-02-23 Biocine Sclavo Mucosal adjuvant
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
WO1995030763A2 (en) 1994-05-09 1995-11-16 Chiron Viagene, Inc. Retroviral vectors having a reduced recombination rate
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
WO1996017072A2 (en) 1994-11-30 1996-06-06 Chiron Viagene, Inc. Recombinant alphavirus vectors
US5482936A (en) 1995-01-12 1996-01-09 Minnesota Mining And Manufacturing Company Imidazo[4,5-C]quinoline amines
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
GB9513261D0 (en) 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
US5707829A (en) 1995-08-11 1998-01-13 Genetics Institute, Inc. DNA sequences and secreted proteins encoded thereby
EP0953052B1 (en) 1996-05-06 2009-03-04 Oxford BioMedica (UK) Limited Crossless retroviral vectors
US5770208A (en) 1996-09-11 1998-06-23 Nabi Staphylococcus aureus B-linked hexosamine antigen
DE69841122D1 (de) 1997-03-10 2009-10-15 Coley Pharm Gmbh Verwendung von nicht-methyliertem CpG Dinukleotid in Kombination mit Aluminium als Adjuvantien
US6818222B1 (en) 1997-03-21 2004-11-16 Chiron Corporation Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
US6080725A (en) 1997-05-20 2000-06-27 Galenica Pharmaceuticals, Inc. Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
AU8586298A (en) 1997-07-25 1999-02-16 University Of Massachusetts Designed protein pores as components for biosensors
EP0905243A2 (en) * 1997-08-05 1999-03-31 Smithkline Beecham Corporation Polynucleotides from Staphylococcus aureus expressed in infected tissue
WO1999011241A1 (en) 1997-09-05 1999-03-11 Smithkline Beecham Biologicals S.A. Oil in water emulsions containing saponins
GB9725084D0 (en) 1997-11-28 1998-01-28 Medeva Europ Ltd Vaccine compositions
EP1053015A2 (en) 1998-02-12 2000-11-22 American Cyanamid Company Pneumococcal and meningococcal vaccines formulated with interleukin-12
US6303114B1 (en) 1998-03-05 2001-10-16 The Medical College Of Ohio IL-12 enhancement of immune responses to T-independent antigens
HUP0101619A3 (en) 1998-04-09 2003-11-28 Smithkline Beecham Biolog Adjuvant compositions
CN1306438A (zh) 1998-05-07 2001-08-01 科里克萨有限公司 佐剂组合物及其使用方法
US6562798B1 (en) 1998-06-05 2003-05-13 Dynavax Technologies Corp. Immunostimulatory oligonucleotides with modified bases and methods of use thereof
US6110929A (en) 1998-07-28 2000-08-29 3M Innovative Properties Company Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
GB9817052D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
WO2000010599A2 (en) 1998-08-19 2000-03-02 North American Vaccine, Inc. IMMUNOGENIC β-PROPIONAMIDO-LINKED POLYSACCHARIDE PROTEIN CONJUGATE USEFUL AS A VACCINE PRODUCED USING AN N-ACRYLOYLATED POLYSACCHARIDE
DK1126876T3 (da) 1998-10-16 2007-07-02 Glaxosmithkline Biolog Sa Adjuvanssystemer og vacciner
WO2000033882A1 (en) 1998-12-04 2000-06-15 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services A vi-repa conjugate vaccine for immunization against salmonella typhi
US20030130212A1 (en) 1999-01-14 2003-07-10 Rossignol Daniel P. Administration of an anti-endotoxin drug by intravenous infusion
US6551600B2 (en) 1999-02-01 2003-04-22 Eisai Co., Ltd. Immunological adjuvant compounds compositions and methods of use thereof
US6355271B1 (en) 1999-02-03 2002-03-12 Biosante Pharmaceuticals, Inc. Therapeutic calcium phosphate particles and methods of manufacture and use
TWI281403B (en) 1999-03-19 2007-05-21 Smithkline Beecham Biolog Vaccine
AU781027B2 (en) 1999-04-09 2005-04-28 Department Of Health & Human Services Recombinant toxin a protein carrier for polysaccharide conjugate vaccines
US6331539B1 (en) 1999-06-10 2001-12-18 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
CA2383110A1 (en) 1999-09-24 2001-03-29 Veronique Henderickx Adjuvant comprising a polyoxyethylene alkyl ether or ester and at least one non-ionic surfactant
WO2001021207A2 (en) 1999-09-24 2001-03-29 Smithkline Beecham Biologicals S.A. Use of combination of polyoxyethylene sorbitan ester and octoxynol as adjuvant and its use in vaccines
WO2001022972A2 (en) 1999-09-25 2001-04-05 University Of Iowa Research Foundation Immunostimulatory nucleic acids
US20010044416A1 (en) 2000-01-20 2001-11-22 Mccluskie Michael J. Immunostimulatory nucleic acids for inducing a Th2 immune response
GB0007432D0 (en) 2000-03-27 2000-05-17 Microbiological Res Authority Proteins for use as carriers in conjugate vaccines
ATE448226T1 (de) 2000-09-01 2009-11-15 Novartis Vaccines & Diagnostic Aza heterocyclische derivate und ihre therapeutische verwendung
DE60132937T2 (de) 2000-09-11 2009-02-12 Novartis Vaccines and Diagnostics, Inc., Emeryville Verfahren zur Herstellung von Benzimidazol-2-yl -Chinolinonderivaten
JP2004509970A (ja) 2000-09-26 2004-04-02 ハイブリドン・インコーポレイテッド 位置的化学変化による免疫刺激オリゴヌクレオチドアナログの免疫刺激活性の調節
US6664265B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Amido ether substituted imidazoquinolines
US6664260B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Heterocyclic ether substituted imidazoquinolines
US6667312B2 (en) 2000-12-08 2003-12-23 3M Innovative Properties Company Thioether substituted imidazoquinolines
US6660747B2 (en) 2000-12-08 2003-12-09 3M Innovative Properties Company Amido ether substituted imidazoquinolines
US6677347B2 (en) 2000-12-08 2004-01-13 3M Innovative Properties Company Sulfonamido ether substituted imidazoquinolines
US6660735B2 (en) 2000-12-08 2003-12-09 3M Innovative Properties Company Urea substituted imidazoquinoline ethers
UA74852C2 (en) 2000-12-08 2006-02-15 3M Innovative Properties Co Urea-substituted imidazoquinoline ethers
US6677348B2 (en) 2000-12-08 2004-01-13 3M Innovative Properties Company Aryl ether substituted imidazoquinolines
US6664264B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Thioether substituted imidazoquinolines
AT410798B (de) * 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
GB0107661D0 (en) * 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
WO2002091998A2 (en) 2001-05-11 2002-11-21 Aventis Pasteur, Inc. Novel meningitis conjugate vaccine
AU2002353764A1 (en) 2001-06-17 2003-03-18 D-Squared Biotechnologies, Inc. Staphylococci surface-exposed immunogenic polypeptides
CA2492826C (en) 2001-09-14 2016-12-13 Cytos Biotechnology Ag Encapsulation of unmethylated cpg-containing oligonucleotides into virus-like particles: method of preparation and use
US20030091593A1 (en) 2001-09-14 2003-05-15 Cytos Biotechnology Ag In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles
WO2003035836A2 (en) 2001-10-24 2003-05-01 Hybridon Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends
UA79764C2 (en) 2001-11-27 2007-07-25 Anadys Pharmaceuticals Inc 3-?-D-RIBOFURANOSYLTHIAZOLO[4,5-d]PYRIDIMINE NUCLEOSIDES AND USES THEREOF
US7321033B2 (en) 2001-11-27 2008-01-22 Anadys Pharmaceuticals, Inc. 3-B-D-ribofuranosylthiazolo [4,5-d] pyrimidine nucleosides and uses thereof
US6677349B1 (en) 2001-12-21 2004-01-13 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
NZ535985A (en) 2002-03-29 2007-04-27 Chiron Corp Substituted benzazoles and use thereof as RAF kinase inhibitors
US6743920B2 (en) 2002-05-29 2004-06-01 3M Innovative Properties Company Process for imidazo[4,5-c]pyridin-4-amines
US7273852B2 (en) 2002-06-13 2007-09-25 The Research Foundation Of The City University Of New York Synthetic C-glycolipid and its use for treating cancer, infectious diseases and autoimmune diseases
JP2006501243A (ja) 2002-08-23 2006-01-12 カイロン コーポレイション グリコーゲンシンターゼキナーゼ３のピロールベースのインヒビター
WO2004060308A2 (en) 2002-12-27 2004-07-22 Chiron Corporation Thiosemicarbazones as anti-virals and immunopotentiators
WO2004064759A2 (en) 2003-01-21 2004-08-05 Chiron Corporation Use of tryptanthrin compounds for immune potentiation
GB0301554D0 (en) 2003-01-23 2003-02-26 Molecularnature Ltd Immunostimulatory compositions
WO2004087153A2 (en) 2003-03-28 2004-10-14 Chiron Corporation Use of organic compounds for immunopotentiation
NZ544542A (en) * 2003-07-24 2009-01-31 Merck & Co Inc Polypeptides for inducing a protective immune response against staphylococcus aureus
US20060188515A1 (en) 2003-07-24 2006-08-24 Anderson Annaliesa S Polypeptides for inducing a protective immune response against staphylococcus aureus
RU2236257C1 (ru) 2003-09-15 2004-09-20 Косяков Константин Сергеевич Синтетический иммуноген для терапии и профилактики злоупотреблений наркотическими и психоактивными веществами
US7771726B2 (en) 2003-10-08 2010-08-10 New York University Use of synthetic glycolipids as universal adjuvants for vaccines against cancer and infectious diseases
CA2555342A1 (en) 2004-02-18 2005-09-01 Merck & Co., Inc. Polypeptides for inducing a protective immune response against staphylococcus aureus
WO2005086663A2 (en) 2004-02-27 2005-09-22 Merck & Co., Inc. Polypeptides for inducing a protective immune response against staphlococcus aureus
US20050222048A1 (en) 2004-03-31 2005-10-06 The Research Foundation Of The City University Of New York Novel synthetic C-glycolipids, their synthesis and use to treat infections, cancer and autoimmune diseases
RU2347586C2 (ru) 2004-04-05 2009-02-27 Пфайзер Продактс Инк. Микрофлюидизированные эмульсии типа "масло в воде" и вакцинные композиции
EP1753441A2 (en) 2004-05-25 2007-02-21 Merck & Co., Inc. Polypeptides for inducing a protective immune response against staphylococcus aureus
WO2006033918A2 (en) 2004-09-17 2006-03-30 Merck & Co., Inc. Polypeptides for inducing a protective immune response against staphylococcus aureus
GB0421079D0 (en) * 2004-09-22 2004-10-27 Glaxosmithkline Biolog Sa Immunogenic composition
CA2583121A1 (en) * 2004-10-21 2007-01-04 Wyeth Immunogenic compositions of staphylococcus epidermidis polypeptide antigens
EP1843785B1 (en) 2005-01-21 2016-07-27 Merck Sharp & Dohme Corp. Polypeptides for inducing a protective immune response against staphylococcus aureus
US20060228368A1 (en) 2005-04-07 2006-10-12 Nabi Biopharmaceuticals Method of protecting against staphylococcal infection
US20060228369A1 (en) 2005-04-11 2006-10-12 Program For Appropriate Technology In Health Stabilization and preservation of temperature-sensitive vaccines
US7691368B2 (en) 2005-04-15 2010-04-06 Merial Limited Vaccine formulations
ATE536884T1 (de) 2005-06-27 2011-12-15 Glaxosmithkline Biolog Sa Immunogene zusammensetzung
US8703095B2 (en) 2005-07-07 2014-04-22 Sanofi Pasteur S.A. Immuno-adjuvant emulsion
GB0526038D0 (en) 2005-12-21 2006-02-01 Glaxosmithkline Biolog Sa Immunogenic composition
FR2896162B1 (fr) 2006-01-13 2008-02-15 Sanofi Pasteur Sa Emulsion huile dans eau thermoreversible
EP2368570A3 (en) 2006-01-18 2012-05-02 University Of Chicago Compositions and methods related to staphylococcal bacterium proteins
AR060188A1 (es) 2006-03-30 2008-05-28 Glaxosmithkline Biolog Sa Procedimiento de conjugacion
EP2476433A1 (en) 2006-03-30 2012-07-18 GlaxoSmithKline Biologicals S.A. Immunogenic composition
EP2043690A1 (en) 2006-06-12 2009-04-08 Nabi Biopharmaceuticals Use of alpha-toxin for treating and preventing staphylococcus infections
ES2397714T3 (es) 2006-10-12 2013-03-08 Glaxosmithkline Biologicals S.A. Vacuna que comprende un adyuvante de emulsión de aceite en agua
WO2008152447A2 (en) 2006-10-30 2008-12-18 The University Of Western Ontario Staphylococcus aureus specific anti-infectives
DE102006062398A1 (de) 2006-12-20 2008-06-26 Edi (Experimentelle & Diagnostische Immunologie) Gmbh Verfahren zur Erkennung und/oder Charakterisierung zellulärer Aktivitätsmuster, Verwendung von Toll-like-Rezeptor-Liganden (TLR-Liganden) und ein Kit
GB0700136D0 (en) * 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Process for manufacturing vaccines
CN101679516B (zh) 2007-05-31 2013-11-13 默沙东公司 靶向金黄色葡萄球菌ORF0657n的抗原结合蛋白
EP2666784B1 (en) * 2007-08-31 2017-04-05 University Of Chicago Methods and compositions related to immunizing against staphylococcal lung diseases and conditions
EP2344189B1 (en) 2008-09-30 2018-05-30 University of Maryland, Baltimore Protective vaccine against staphylococcus aureus biofilms comprising cell wall-associated immunogens
EP2208787A1 (en) 2009-01-19 2010-07-21 Université de Liège A recombinant alpha-hemolysin polypeptide of Staphylococcus aureus, having a deletion in the stem domain and heterologous sequences inserted
ES2565377T3 (es) * 2009-04-14 2016-04-04 Glaxosmithkline Biologicals Sa Composiciones para inmunización contra Staphylococcus aureus

Also Published As

Publication number Publication date
US9205142B2 (en) 2015-12-08
SMT201600117B (it) 2016-07-01
BRPI1013780A2 (pt) 2019-07-02
US8632783B2 (en) 2014-01-21
HUE028803T2 (en) 2017-01-30
US20170340720A1 (en) 2017-11-30
US10195263B2 (en) 2019-02-05
JP5830009B2 (ja) 2015-12-09
ZA201302878B (en) 2013-12-23
JP7109412B2 (ja) 2022-07-29
HRP20160276T1 (hr) 2016-04-08
MX2019003004A (es) 2019-08-05
MX2011010735A (es) 2012-01-25
CN109248313B (zh) 2023-01-17
CA2758490A1 (en) 2010-10-21
BRPI1013780B1 (pt) 2021-09-14
CO6440592A2 (es) 2012-05-15
PL2510947T3 (pl) 2016-09-30
MX363222B (es) 2019-03-15
EP2510947B1 (en) 2016-02-10
EP3263128A2 (en) 2018-01-03
US8679505B2 (en) 2014-03-25
CN102647999A (zh) 2012-08-22
ES2565377T3 (es) 2016-04-04
KR20120034612A (ko) 2012-04-12
PH12015500092A1 (en) 2015-12-02
NZ612315A (en) 2014-10-31
SG175092A1 (en) 2011-11-28
US9642904B2 (en) 2017-05-09
EP3263128A3 (en) 2018-01-24
US20120093850A1 (en) 2012-04-19
RU2011146016A (ru) 2013-05-20
US20160158335A1 (en) 2016-06-09
BRPI1013780B8 (pt) 2022-10-04
JP2016020390A (ja) 2016-02-04
DK2510947T3 (en) 2016-03-21
JP2012523246A (ja) 2012-10-04
IL215593A0 (en) 2011-12-29
RU2508126C2 (ru) 2014-02-27
US20140178425A1 (en) 2014-06-26
RU2013154779A (ru) 2015-06-20
JP2017193574A (ja) 2017-10-26
JP2022078317A (ja) 2022-05-24
CA3154626A1 (en) 2010-10-21
AU2010238255A1 (en) 2011-11-03
AU2010238255B2 (en) 2014-10-16
SG10201404076TA (en) 2014-10-30
NZ595689A (en) 2014-03-28
CA2758490C (en) 2023-05-02
WO2010119343A8 (en) 2012-04-26
WO2010119343A3 (en) 2011-04-07
CN109248313A (zh) 2019-01-22
JP2020007351A (ja) 2020-01-16
EP2419129A2 (en) 2012-02-22
EP2510947A1 (en) 2012-10-17
US20120107340A1 (en) 2012-05-03
WO2010119343A2 (en) 2010-10-21

Similar Documents

Publication Publication Date Title
IL215593A0 (en) Compositions for immunising against staphylococcus aureus
IL257695B (en) Fungicides
GB2473460B (en) Antimicrobial Composition
SI2344170T1 (sl) Antimikrobni sestavki
ZA201301479B (en) Fungicidal compositions
ZA201305193B (en) Antimicrobial composition
ZA201104108B (en) Antimicrobial compositions
PL2461692T3 (pl) Synergistyczna kompozycja biobójcza
PL2458993T3 (pl) Synergistyczna kompozycja przeciwdrobnoustrojowa
PL2461693T3 (pl) Synergistyczna kompozycja biobójcza
GB0909030D0 (en) Antibacterial composition
GB2472315B (en) Antibacterial compositions
PL2633019T3 (pl) Środek piorący lub czyszczący o działaniu przeciwdrobnoustrojowym
IL216853A0 (en) Agricultural compositions
GB0920891D0 (en) Herbicidal compositions
IL214207A0 (en) Agricultural compositions
ZA201307018B (en) Antimicrobial composition
GB0903955D0 (en) Fungicidal compositions
PL2485588T3 (pl) Synergistyczna kompozycja biobójcza
GB0919690D0 (en) compositions for immunising against staphylococcus aureus
ZA201403911B (en) Antimicrobial composition
HK1167340A (en) Compositions for immunising against staphylococcus aerus
GB0910411D0 (en) Antibacterial compositions
GB201111128D0 (en) Antimicrobial compositions
GB201002594D0 (en) Antimicrobial compositions